The U.S. Food and Drug Administration issued a Complete Response Letter to UCB regarding the Belgium-based company’s Biologics License Application for bimekizumab for adults with moderate to severe plaque psoriasis.

Spending time in the sun without protection increases the risk of melanoma, but the potentially deadly skin cancer can occur even on sites with minimal sun exposure, doctors warn.

The U.S. Food and Drug Administration approved Bausch Health Companies Inc.’s topical plaque psoriasis treatment Duobrii, which is expected to be a key revenue driver for the company.

South San Francisco-based Harpoon Therapeutics is tapping into the white-hot IPO magic that was one of the hallmarks of 2018 for the biotech industry.

Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.

Celgene Corporation announced results from the phase 3 STYLE study, which showed that Otezla (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment response at week 16 compared with placebo.

Bausch Health, formerly Valeant Pharmaceuticals, received tentative U.S. approval to market the plaque psoriasis lotion Bryhali.

The U.S. Food and Drug Administration approved the first non-radioactive, dual-tracer for sentinel lymph node biopsy.

According to a new study published in Neurology, researchers discovered increased biomarkers for Alzheimer’s in the brains of older patients with high blood pressure, as opposed to those who have average blood pressure readings, CNN reported.

Aclaris Therapeutics Inc.’s drug to treat a common type of skin growth called seborrheic keratoses received FDA clearance.